US Market News
4月前
Anti-Aging Protein Research Takes a Step Forward with Cell CloningMarch 24, 2026 11:05 AM
PR Newswire (Canada)
Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 24, 2026 /CNW/ -- Equity-Insider.com — A protein called a-Klotho circulating in the bloodstream protects the brain, heart, kidneys, and the immune system. Peer-reviewed research has linked higher Klotho levels to reduced risk of Alzheimer's, cardiovascular disease, and certain cancers. Mayo Clinic research connects declining Klotho to arterial stiffness and vascular calcification.
The challenge is that the body cuts production of this protein by approximately 50% after the age of 40. The molecule that guards against the deadliest age-related diseases starts to decline just as the risk for these conditions starts to rises. Market projections highlight the scale of the issue: Alzheimer's alone is projected to reach $32.8 billion by 2033, cardiovascular disease remains the leading global cause of death, and kidney disease affects 850 million people worldwide.The global cell therapy market has surpassed $8.2 billion in 2026. The broader cell and gene therapy sector is forecast to surge from $10.4 billion to more than $45 billion by 2035, with more than 40 FDA-approved products now on the market. Regenerative medicine alone is projected to reach $578 billion by 2033. The science of reversing biological decline is no longer theoretical, it is an industry. And the companies building the cellular foundations for these therapies are at the forefront of market attention.Vertex Pharmaceuticals (NASDAQ: VRTX) demonstrated what that looks like at scale. The company's gene-edited cell therapy Casgevy — developed with CRISPR Therapeutics (NASDAQ: CRSP) — became the world's first approved CRISPR-based treatment, now available for sickle cell disease and transfusion-dependent beta-thalassemia. Vertex expects to file regulatory submissions for the 5–11 age group in the first half of 2026. CRISPR Therapeutics, meanwhile, reported Phase 1 data showing its in vivo gene-editing therapy CTX310 achieved mean reductions of 73% in ANGPTL3, 55% in triglycerides, and 49% in LDL cholesterol after a single intravenous infusion — a one-dose cardiovascular intervention that could reshape metabolic disease treatment.Altimmune (NASDAQ: ALT) is advancing pemvidutide, a GLP-1/glucagon dual receptor agonist for metabolic disease that targets the $65 billion metabolic syndrome opportunity through hormonal regulation of fat metabolism. Arrowhead Pharmaceuticals (NASDAQ: ARWR) dosed the first patients in a Phase 1/2a trial of ARO-DIMER-PA, the first clinical candidate designed to silence two genes simultaneously for atherosclerotic cardiovascular disease. These are platform-level interventions pulling institutional capital into longevity and regenerative medicine at unprecedented speed.But before any cell therapy can reach patients, it needs a starting point. And that's the step one this company just completed.Avaí Bio (OTCQB: AVAI) recently announced a critical early-stage milestone alongside joint venture partner Austrianova: beginning the creation of a Master Cell Bank (MCB) of genetically modified cells that overexpress the a-Klotho protein. An MCB is the process of taking a single genetically engineered cell and cloning it into tens of millions of identical copies, creating a standardized, GMP-compliant bank of cellular starting material. It's the essential foundation from which all future working cell banks and therapy development will proceed — the step that ensures consistency, quality, and scalability before any therapeutic product can be developed."We are excited to enter the first step in the production phase of a-Klotho producing cells as part of our commitment to deliver safe, effective treatments for aging associated diseases," said Chris Winter, CEO of Avaí Bio.The cells banked in the MCB will be used in conjunction with Austrianova's proprietary Cell-in-a-Box® encapsulation technology, which protects therapeutic cells inside a biocompatible shell to allow continuous protein secretion without triggering immune rejection. The technology is backed by over 50 peer-reviewed publications and decades of development. Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, each leveraging this same encapsulation technology. The company participated in the 15th European Pancreas and Islet Transplantation Association Symposium in January 2026, where Dr. Eva Maria Lilli Brandtner evaluated advanced cells for potential application in diabetes therapy.The protein that protects against the most serious age-related diseases is steadily disappearing from the bloodstream. The science to potentially restore it exists. And the company that just created the standardized cellular foundation to advance that science — Avaí Bio (OTCQB: AVAI) — is doing so in a market where every platform capable of developing cell-based therapeutics is being re-evaluated.For more information on Avaí Bio (OTCQB: AVAI) and its Klothonova and Insulinova programs, visit Equity-Insider.comRead this and more news for Avaí Bio at: Equity-Insider.comArticle Source: https://usanewsgroup.com/avai-profile/ CONTACT:
EQUITY INSIDER
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avaí Bio, Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Avaí Bio, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avaí Bio, Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avaí Bio, Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:Straits Research, Global Cell Therapy Market 2026 — https://straitsresearch.com/report/cell-therapy-marketPrecedence Research, Cell and Gene Therapy Market Forecast — https://www.precedenceresearch.com/cell-and-gene-therapy-marketGrand View Research, CAR T-Cell Therapy Market — https://www.grandviewresearch.com/industry-analysis/car-t-cell-therapy-market-reportAstute Analytica, Regenerative Medicine Market 2025–2033 — https://www.globenewswire.com/news-release/2026/01/27/3226653/0/en/Regenerative-Medicine-Market-Review-2020-2024-and-Forecast-2025-2033-A-578-29-Bn-Opportunity-Says-Astute-Analytica.html Logo: https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/anti-aging-protein-research-takes-a-step-forward-with-cell-cloning-302723584.html
Original: Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
US Market News
5月前
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AFebruary 17, 2026 9:00 AM
InvestorsHub NewsWireFebruary 17th, 2026 -- InvestorsHub NewsWire -- via BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (Profile), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system ("CNS") indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-ß antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system ("CNS") drug delivery designed to delivery drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics' position in the oncology and CNS sectors as the OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), MeiraGTx Holdings plc (NASDAQ:MGTX), Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) and Johnson & Johnson (NYSE:JNJ).
Central nervous system disorders such as brain cancer, Alzheimer's Disease, Parkinson's Disease and others represent one of the largest and most challenging therapeutic categories in modern medicine.
The convergence ance of CNS and oncology makes Oncotelic's update on expanding international IP coverage for OT-101 even more impactful.
Oncotelic Therapeutics' focus on delivery approaches relevant to CNS and oncology aligns with the industry's direction.
Oncotelic Therapeutics' development of OT-101 demonstrates its advanced R&D capabilities and innovative repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research.
Oncotelic Therapeutics positions itself with a diversified portfolio spanning oncology-focused therapies, CNS indications and delivery technologies.
Click here to view the custom infographic of the Oncotelic Therapeutics editorial.
Big Pharma's Shift Toward Proven Assets
Biopharma dealmaking has increasingly centered on external innovation, licensing, and acquisitions of assets that demonstrate clinical validation. Strategic analyses from McKinsey & Company describe continued reliance on partnerships and acquisitions to replenish pipelines as internal R&D productivity challenges persist. Similarly, Deloitte's life sciences M&A outlook highlights ongoing selectivity and capital discipline, encouraging companies to prioritize assets with clearer development paths and measurable progress toward commercialization.
This strategic pivot reflects economic realities. Drug-development timelines remain long and costly, and investors have increasingly favored programs that demonstrate human safety or efficacy signals. Late-stage assets can reduce scientific uncertainty because clinical data provides clearer insight into safety profiles, dosing parameters, and potential regulatory pathways. As a result, companies nearing pivotal studies or late clinical phases may attract greater interest from acquirers seeking faster paths to market entry.
Oncology and CNS programs have emerged as particularly strategic targets within this framework. Oncology continues to dominate pharmaceutical pipelines due to large commercial markets and ongoing innovation, while CNS disorders represent some of the most significant unmet medical needs globally. Assets that bridge these areas may offer differentiated positioning, especially when they address complex biological pathways or delivery challenges that have historically limited therapeutic success.
Platforms supported by existing human data also carry valuation advantages. Programs that demonstrate clinical activity provide tangible milestones that investors can evaluate, reducing uncertainty compared with early discovery-stage platforms. This dynamic is contributing to growing attention toward companies holding clinical-stage portfolios rather than single preclinical assets.
Oncotelic Therapeutics fits this strategic profile through its clinical-stage pipeline focused on oncology and CNS-related targets. A clinical-stage biopharmaceutical developer, the company is pursuing therapies for cancer and other serious conditions. Oncotelic's programs, including those targeting TGF-ß signaling and delivery-focused approaches, align with the broader industry emphasis on validated mechanisms and diversified development strategies.
CNS, Oncology Markets Are Converging
Central nervous system disorders represent one of the largest and most challenging therapeutic categories in modern medicine. The World Health Organization reports that neurological conditions are now among the leading causes of disability and illness worldwide, affecting more than one in three people globally. The growing burden of neurodegenerative disease has intensified the need for innovative treatments capable of addressing complex biological mechanisms.
Alzheimer's disease illustrates the scale of this unmet need. The Alzheimer's Association estimates that millions of Americans currently live with the disease and that the economic burden continues to rise sharply, reflecting both healthcare costs and societal impact. Parkinson's disease shows similar trends, with prevalence expected to increase as populations age, reinforcing the long-term importance of CNS therapeutic innovation.
The intersection between oncology and CNS research is becoming increasingly relevant because many biological pathways operate across disease categories. Immune regulation, inflammation and signaling pathways involved in tumor progression can also influence neurological disease processes. These overlaps create opportunities for therapeutic platforms that can be developed across multiple indications, potentially expanding commercial reach while leveraging shared scientific insights.
From an investment perspective, cross-indication platforms may offer strategic advantages by enabling companies to pursue multiple markets simultaneously. Pharmaceutical companies evaluating acquisitions often look for mechanisms that extend beyond a single indication, as this can increase potential return on investment and support lifecycle management strategies.
Oncotelic Therapeutics' development strategy reflects this convergence by focusing on pathways such as TGF-ß modulation, which has been extensively studied in oncology and immune regulation contexts. Research documents the role of TGF-ß signaling in cancer biology and tumor microenvironment regulation. By targeting mechanisms relevant across multiple disease categories, the company aligns with the broader trend toward integrated therapeutic platforms.
New Milestones Expand Long-Term Potential
This convergence makes Oncotelic's update on expanding international IP coverage for OT-101, it's proprietary TGF-ß antisense therapeutic platform, even more impactful. The company, along with Sapu Bioscience, noted that the platform "[strengthens] protection across neurology, oncology, and central nervous system ("CNS") drug delivery."
OT-101 has multiple prior clinical trials conducted in various oncology indications including glioblastoma and pancreatic cancers. The compound was also investigated for additional applications in Acute Respiratory Distress Syndrome ("ARDS") and COVID-19-related inflammatory conditions. Building on its established clinical foundation in oncology, the Company is advancing OT-101 as a broader central nervous system ("CNS")-capable therapeutic platform, supported by targeted delivery technologies and expanded intellectual property coverage.
The update noted that in Australia, the company has received allowed patent claims explicitly covering OT-101 for the treatment of Parkinson's disease, while in China and Germany, utility model patents have been granted that provide device-level protection for continuous intracranial infusion technologies relevant to CNS therapeutics. "Collectively, these IP developments establish an integrated OT-101 CNS commercialization platform, combining therapeutic use claims in neurology with granted delivery-device protection," stated the company, which believes this expanded IP estate enhances OT-101's strategic value and supports future development, partnering, and commercialization efforts across oncology and neurological indications.
"OT-101 has a well-established clinical foundation, including prior clinical trials in multiple oncology indications, including glioblastoma, and these new IP milestones significantly expand its long-term potential," said Oncotelic CEO Dr. Vuong Trieu. "By securing Parkinson's disease claims in Australia and strengthening CNS delivery protection in China and Germany, we are building a globally defensible platform that supports both therapeutic use and delivery, while positioning the company for strategic partnerships and long-term shareholder value creation."
Drug Delivery Emerges as Strategic Differentiator
Drug delivery has become an increasingly important focus area within biotech innovation, particularly for CNS therapies. The blood–brain barrier presents a significant biological obstacle, preventing many drugs from reaching effective concentrations within brain tissue. Peer-reviewed research highlights that this barrier can limit therapeutic success even when a drug demonstrates strong activity in preclinical models.
Because of these challenges, delivery technologies capable of improving targeting or bioavailability are gaining strategic importance. Researchers increasingly view delivery systems as enabling technologies that can unlock previously inaccessible therapeutic pathways. Rather than viewing delivery as secondary to molecular discovery, investors and developers are recognizing it as a critical component of therapeutic success. Regulatory agencies also acknowledge the importance of delivery innovation. The U.S. Food and Drug Administration maintains specific frameworks for evaluating combination products that integrate drug and device components, underscoring the role administration methods play in clinical outcomes
From a strategic standpoint, companies developing delivery technologies alongside therapeutic mechanisms may offer differentiated value propositions. Improved delivery can enhance safety, reduce systemic toxicity, or increase efficacy by concentrating treatment within target tissues.
Oncotelic Therapeutics' focus on delivery approaches relevant to CNS and oncology aligns with this industry direction. By emphasizing methods that may enhance therapeutic targeting and overcome biological barriers, the company operates within a segment increasingly viewed as a critical bottleneck, and therefore a strategic value driver, in modern drug development.
Platform Repositioning Drives Capital Efficiency
Biotech strategy increasingly emphasizes capital efficiency, and one emerging approach involves repositioning clinically validated mechanisms into additional therapeutic indications. Rather than starting from entirely new discovery programs, companies are expanding existing platforms into adjacent markets where scientific rationale already exists.
This strategy can reduce risk because safety data and mechanistic understanding from earlier studies may inform future development pathways. Repositioning also allows companies to maximize the value of prior investments by generating multiple clinical opportunities from a single biological target or technology platform.
The TGF-ß pathway provides a strong example of this approach. Extensive scientific literature describes its role in tumor growth, immune modulation and inflammation, creating opportunities for therapies targeting this pathway across multiple diseases. Advances in understanding tumor microenvironment biology have renewed interest in therapeutic strategies that modulate TGF-ß signaling.
Oncotelic Therapeutics' development of OT-101, which targets TGF-ß2 mRNA, illustrates a repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research. Studies investigating OT-101 in combination with standard therapies reflect ongoing efforts to expand its potential clinical applications.
Platform repositioning may also enhance strategic flexibility for potential partners or acquirers. Companies capable of adapting mechanisms to multiple disease contexts can respond to evolving market conditions or regulatory landscapes, increasing long-term development optionality.
Diversified Pipelines Reduce Binary Investment Risk
Historically, biotech investment has often centered on single-asset companies, where success or failure depended heavily on one clinical outcome. However, diversified pipelines are increasingly viewed as advantageous because they distribute risk across multiple programs and timelines.
A multiasset strategy can provide resilience during clinical development, as setbacks in one program may be offset by progress in others. This diversification can also create multiple value inflection points, attracting investors seeking reduced exposure to binary outcomes while maintaining exposure to breakthrough innovation.
From an M&A perspective, diversified pipelines may increase strategic appeal because acquirers gain optionality. A single acquisition can provide access to multiple therapeutic candidates, allowing pharmaceutical companies to prioritize programs based on evolving market needs or scientific progress.
As the biotech industry continues to emphasize late-stage validation, platform versatility and capital efficiency, companies combining diversified clinical programs with differentiated scientific approaches may increasingly attract attention from strategic partners and acquirers seeking to balance innovation with reduced development risk.
Oncotelic Therapeutics positions itself within this diversified model through a portfolio spanning oncology-focused therapies, CNS indications and delivery technologies. The company's pipeline includes multiple assets at varying development stages, which may reduce reliance on a single program outcome while supporting broader strategic positioning.
Pharma Deals Signal Strategic Shift
The pharmaceutical space continues to evolve through strategic partnerships, targeted acquisitions and collaborative innovation designed to accelerate drug development and expand therapeutic pipelines. Recent announcements across the sector highlight a focus on neurological disorders, RNA-based therapies and AI-driven research approaches, reflecting how leading operators are positioning themselves to capture future growth opportunities while addressing significant unmet medical needs.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported a global licensing and collaboration agreement with Novartis. The agreement is for ARO-SNCA, Arrowhead's preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson's disease, and for other additional collaboration targets that will utilize Arrowhead's proprietary Targeted RNAi Molecule (TRiM[TM]) platform. Upon closing, Arrowhead will receive $200 million as an upfront payment and is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales.
MeiraGTx Holdings plc (NASDAQ:MGTX) announced the formation of a joint venture with Hologen Limited. According to the announcement, MeiraGTx will receive $200 million in upfront cash at closing of the JV, called Hologen Neuro AI Ltd. In addition to the $200 million upfront payment to MeiraGTx, Hologen Neuro AI will be funded with committed capital of up to $230 million from Hologen to fully finance the development of AAV-GAD for the treatment of Parkinson's disease through to commercialization, as well as funding earlier stage clinical programs in the CNS, including AAV-BDNF for genetic obesity. Hologen will contribute its proprietary multi-modal generative foundation models ("LMMs") to the joint venture.
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) completed the acquisition of Sage Therapeutics for approximately $561 million upfront, with contingent value rights ("CVR") that could bring total consideration up to about $795 million. The transaction will provide Supernus with an innovative marketed product: ZURZUVAE(R) (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration ("FDA")-approved oral medicine indicated for the treatment of adults with postpartum depression.
Johnson & Johnson (NYSE:JNJ) has entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies in a $14.6 billion transaction. Intra-Cellular Therapies is a biopharmaceutical company focused on the development and commercialization of therapeutics for CNS disorders. With this agreement, Johnson & Johnson adds Intra-Cellular Therapies' CAPLYTA(R)(lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
These developments underscore a broader transformation underway in pharma, where collaboration, platform technologies and portfolio expansion are becoming central to long-term strategy. As companies pursue high-value deals and innovative partnerships, investors and industry observers alike are watching closely to see how these initiatives translate into clinical advancement, commercial success and sustained competitive advantage.
For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.
About BioMedWire
BioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, "Biotech" to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Original: Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
US Market News
5月前
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationJanuary 29, 2026 1:31 PM
PR Newswire (US)
Issued on behalf of Avant Technologies Inc.VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- USA News Group News Commentary – Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27 trillion by 2030[1]. This transition is moving the entire healthcare sector toward regenerative medicine which is projected to reach $578.59 billion by 2033[2]. We are witnessing a total structural reset that creates massive upside for bio-restorative platforms capable of a systemic re-rating. This emerging investment class includes Avant Technologies, Inc. (OTCQB: AVAI), MannKind (NASDAQ: MNKD), Altimmune (NASDAQ: ALT), Lineage Cell Therapeutics (NYSE-A: LCTX), and Arrowhead Pharmaceuticals (NASDAQ: ARWR).
The latest data shows cell therapy markets hitting $8.85 billion by 2026[3] while AI-driven drug discovery platforms are accelerating to $24.51 billion[4]. These figures confirm that institutions are now positioning for the convergence of cell-encapsulation technology and precision metabolic delivery. This structural shift is opening a massive window for platforms that can address the $65.2 billion metabolic syndrome opportunity with curative infrastructure rather than simple symptom management. For the smart money, these cell-based and gene-targeted therapies are officially the longevity alpha of the 2026 cycle.Avant Technologies, Inc. (OTCQB: AVAI) made waves at the 15th European Pancreas and Islet Transplantation Association (EPITA) Symposium, where Dr. Eva Maria Lilli Brandtner is evaluating advanced cells for potential application in a diabetes therapy. The Austria-based event, which ran January 25-27, 2026, brought together global scientists and clinicians focused on biological therapies for diabetes. EPITA stands as one of the world's flagship associations for networking on islet transplantation and beta cell replacement, making Avant's participation particularly significant for the emerging biotechnology company.Dr. Brandtner is assessing promising cells for inclusion with Avant's Cell-in-a-Box® technology, developed in partnership with SGAustria Pte. Ltd. This clinically proven microencapsulation platform solves a critical problem: when doctors transplant therapeutic cells into patients, the immune system typically destroys them within days or weeks. The traditional solution requires lifelong immunosuppressive drugs that carry serious risks, including infections, organ damage, and elevated cancer risk."While stem cell-derived beta cells undoubtedly represent a breakthrough in unlimited insulin sources, immune protection still remains a key challenge," Dr. Brandtner said. "Avant's Cell-in-a-Box® technology addresses this effectively, positioning us to contribute meaningfully to beta cell replacement therapies for type 1 and insulin-dependent type 2 diabetes patients worldwide."The cell encapsulation technology creates a protective barrier around therapeutic cells while still allowing nutrients, oxygen, and therapeutic proteins to pass through freely. This approach eliminates the need for immunosuppressive drugs while preventing potential complications such as cell escape or tumor formation, making it a cornerstone for safe and scalable diabetes therapies.Avant operates through two joint ventures targeting massive markets. Insulinova, Inc. partners with SGAustria to develop treatments for type 1 diabetes and insulin-dependent type 2 diabetes. The approach uses genetically modified cells that produce, regulate, and store insulin, essentially creating a bioartificial pancreas that restores natural glucose control. The diabetes market opportunity is substantial: 589 million people globally live with type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050 according to the International Diabetes Federation.The second venture, Klothonova, partners with Singapore-based Austrianova to develop therapies for age-related diseases and anti-aging therapies using cells that produce the Klotho protein. Research from the Mayo Clinic links declining Klotho levels to arterial stiffness, endothelial dysfunction, and vascular calcification.Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span Alzheimer's disease ($32.8 billion by 2033), cardiovascular disease (32% of global deaths), and kidney disease (850 million affected worldwide).CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/MannKind Corporation (NASDAQ: MNKD) announced FDA approval of an updated Prescribing Information for Afrezza (insulin human) Inhalation Powder, revising recommendations for starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens including multiple daily injections or insulin pump therapy. The updated initial conversion table is based on clinical trials in adults showing significantly improved mealtime glycemic excursions with the revised dosing approach."We expect that this label update will help support healthcare providers by providing clearer starting dose guidance when transitioning patients to inhaled insulin from subcutaneous mealtime insulin—whether injections or insulin pumps," said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Diabetes at MannKind. "We believe this refinement to the label helps support appropriate initiation of therapy while reinforcing Afrezza's established clinical profile."The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study and INHALE-3 trial demonstrating improved postprandial glucose outcomes following conversion to inhaled insulin using the now-approved conversion dose. Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in adult patients with diabetes mellitus, administered at the beginning of meals using a small portable inhaler that delivers insulin via MannKind's proprietary Technosphere technology.Altimmune (NASDAQ: ALT) received FDA Breakthrough Therapy Designation for pemvidutide for treatment of patients with metabolic dysfunction-associated steatohepatitis. Breakthrough Therapy Designation is intended to expedite development and review of medicines treating serious conditions that have shown preliminary clinical evidence indicating potential for substantial improvement over available therapies."The FDA's Breakthrough Therapy Designation for pemvidutide in MASH reinforces the promise of its clinical profile and potential to address significant unmet needs in this serious, progressive liver disease," said Jerry Durso, President and CEO of Altimmune. "As I step into the CEO role, this designation represents an important validation for pemvidutide."Altimmune completed a productive end-of-phase 2 meeting with the FDA resulting in alignment on parameters for a registrational Phase 3 trial of pemvidutide in MASH patients with moderate to advanced liver fibrosis. The company plans to initiate a Phase 3 trial evaluating multiple pemvidutide doses over a 52-week treatment period incorporating biopsy-based endpoints to support a potential accelerated approval.Lineage Cell Therapeutics (NYSE-A: LCTX) has received delivery of a novel gene-edited hypoimmune cell line from Factor Bioscience under their strategic collaboration. The proprietary induced pluripotent stem cell line contains hypoimmunity edits designed to support non-immune privileged indications and includes an additional disease-specific edit with potential to differentiate this cell line from competing therapies."Our partnership with Factor supports our plan to create novel and superior product candidates by combining our manufacturing and process development capabilities with cutting-edge cell engineering and editing technologies," stated Brian M. Culley, CEO of Lineage Cell Therapeutics. "This achievement under our collaboration with Factor supports our plan to broaden our cell therapy platform through the addition of new technologies and indications, as we await further updates from our lead cell therapy program, OpRegen, for dry age-related macular degeneration with geographic atrophy."Lineage will evaluate the cell line for its ability to adapt to the company's proprietary AlloSCOPE manufacturing platform. The clinical-stage biotechnology company develops allogeneic cell therapies for serious medical conditions with a pipeline including OpRegen for retinal disease and OPC1 for spinal cord injuries.Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the first clinical candidate designed to silence expression of two genes simultaneously in one molecule for treatment of atherosclerotic cardiovascular disease due to mixed hyperlipidemia. The investigational RNA interference therapeutic targets both proprotein convertase subtilisin kexin 9 and apolipoprotein C3 genes, representing an important step forward enabled by Arrowhead's proprietary Targeted RNAi Molecule platform."Arrowhead is at the forefront of innovation in the RNAi field, and we're proud of the versatile capabilities of our TRiM platform, now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule," said Chris Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. "ARO-DIMER-PA is designed to silence both the PCSK9 and APOC3 genes, which together have substantial clinical validation as important targets for reducing LDL-cholesterol, triglycerides, and total atherogenic lipoproteins."In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3 and ameliorated high levels of non-HDL-cholesterol, LDL-cholesterol, and triglycerides in hyperlipidemic nonhuman primates. The initiation advances Arrowhead's growing cardiometabolic portfolio including commercial product REDEMPLO approved in the United States, Canada, and China for familial chylomicronemia syndrome, ongoing Phase 3 study of zodasiran in homozygous familial hypercholesterolemia, and Phase 1/2 studies of ARO-INHBE and ARO-ALK7 for obesity.Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES CITED:https://theweek.com/business/longevity-economy-booming-live-longerhttps://www.globenewswire.com/news-release/2026/01/27/3226653/0/en/Regenerative-Medicine-Market-Review-2020-2024-and-Forecast-2025-2033-A-578-29-Bn-Opportunity-Says-Astute-Analytica.htmlhttps://www.towardshealthcare.com/insights/cell-therapy-market-sizinghttps://www.towardshealthcare.com/insights/artificial-intelligence-in-drug-discovery Logo - https://mma.prnewswire.com/media/2838876/5742703/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html
Original: Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Paullee
8月前
Zilla
1年前
PonkenPlonken
2年前
Monksdream
2年前
Biorat
3年前
MiamiGent
3年前
whytestocks
6年前
ClayTrader
6年前
crudeoil24
6年前
$treet $inatra
6年前
メールアドレスで登録
